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Molecular monitoring of chronic myeloid leukemia patients using robust BCR-ABL1 tests standardized to the International Scale (IS) is
key to proper disease management, especially when treatment cessation is considered. Most laboratories currently use a time-
consuming sample exchange process with reference laboratories for IS calibration. A World Health Organization (WHO) BCR-ABL1
reference panel was developed (MR1–MR4), but access to the material is limited. In this study, we describe the development of the first
cell-based secondary reference panel that is traceable to and faithfully replicates the WHO panel, with an additional MR4.5 level. The
secondary panel was calibrated to IS using digital PCR with ABL1, BCR and GUSB as reference genes and evaluated by 44 laboratories
worldwide. Interestingly, we found that440% of BCR-ABL1 assays showed signs of inadequate optimization such as poor linearity and
suboptimal PCR efficiency. Nonetheless, when optimized sample inputs were used, 460% demonstrated satisfactory IS accuracy,
precision and/or MR4.5 sensitivity, and 58% obtained IS conversion factors from the secondary reference concordant with their current
values. Correlation analysis indicated no significant alterations in %BCR-ABL1 results caused by different assay configurations. More
assays achieved good precision and/or sensitivity than IS accuracy, indicating the need for better IS calibration mechanisms.
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INTRODUCTION
The development of BCR-ABL1 tyrosine kinase inhibitors, from the
first-generation imatinib to newer agents such as nilotinib and
dasatinib, has enabled progressively deeper molecular responses
in chronic myeloid leukemia (CML) patients undergoing tyrosine
kinase inhibitor therapy.1,2 Deeper molecular responses are
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defined as BCR-ABL1 levels of ⩽ 0.01% (MR4) and ⩽ 0.0032% (MR4.5)
on the international reporting scale (International Scale (IS)) and
are important milestones for patients considering treatment
cessation.3 Other landmarks on the IS also represent different
treatment decision thresholds and prognostic outcomes.4 For
example, patients who reach 10% IS or below at 3 months after
treatment have significantly higher rates of MR4.5 by 5 years,5 and
reaching 0.1% IS (major molecular response) by 12 months of
treatment is predictive of subsequently achieving undetectable
BCR-ABL1 levels.6 Thus, regular molecular monitoring using real-
time reverse-transcription quantitative PCR (RT-qPCR) is recom-
mended for optimal disease management, and treatment
decisions rely on achieving milestone molecular responses in
the first year of therapy and beyond.2,7
As treatment decisions are directly impacted by test results,
accuracy and precision of BCR-ABL1 assays across the entire
measurement range is crucial for patient management, especially
in patients with deep molecular responses when considering
possible treatment cessation. It is well known that high variability
exists between RT-qPCR methods used in different laboratories.8,9
The first international standardization attempt occurred in 2003,
when different BCR-ABL1 assays used in the International
Randomised Study of Interferon versus STI571 (IRIS) trial
established IS based on 30 CML patient samples.10 Subsequently,
a process for establishing a test-specific IS conversion factor (CF)
by exchanging 20–30 CML patient samples with a reference
laboratory was developed.11 Although this process works well for
laboratories with tests that show good stability over time, it is time
consuming, expensive and difficult to access for smaller
laboratories.12,13
In 2010, the ‘first International Genetic Reference Panel for
quantitation of BCR-ABL mRNA’ was developed as a primary
standard for BCR-ABL1 assay IS calibration and accredited by the
World Health Organization (WHO).14 The WHO panel is made of
lyophilized K562 and HL-60 cell line mixtures, which allows the
inclusion of cellular RNA extraction in the IS calibration against the
two major BCR-ABL1 breakpoints (e13a2 and e14a2) and carries
three sets of nominal %BCR-ABL1 values using ABL1, BCR and
GUSB as reference genes. Owing to restricted access, the WHO
panel is currently only available to manufacturers of BCR-ABL1 test
kits and secondary standards.13 The commercial secondary
standards available to date are made of RNA;15,16 thus, RNA
extraction is not included in the IS calibration process, except
when the standards are artificially spiked into the cell samples.
Furthermore, none of these are calibrated to the WHO panel
against all three reference genes.
In this study, we describe the successful development of the
first cell-based BCR-ABL1 secondary reference panel that is
traceable to and faithfully replicates the WHO panel in both raw
materials (lyophilized K562 and HL-60 cell mixes) and manufactur-
ing process, with the addition of a MR4.5 level. Nominal %BCR-
ABL1 IS values were assigned to the secondary panel using
reverse-transcription droplet digital PCR (RT-ddPCR) against ABL1,
BCR and GUSB. The secondary panel was successfully evaluated by
45 different BCR-ABL1 assays in a subsequent international multi-
center evaluation study.
MATERIALS AND METHODS
Manufacturing and IS calibration of secondary reference panel
K562 (ATCC CCL-243) and HL-60 cells (ATCC CCL-240) (American Type
Culture Collection, Manassas, VA, USA) were cultured, mixed and
lyophilized following methods described by White et al.14 with minor
modifications (Supplementary Information). Calibration to the WHO
standards was performed as described.14 IS calibration using ABL1 as a
reference gene was conducted using 10 sets of WHO ‘first International
Genetic Reference Panel for quantitation of BCR-ABL mRNA’ panels
(National Institute for Biological Standards and Control, South Mimms,
UK). Calibration using BCR and GUSB was conducted in a second study
using another 10 sets of WHO panels. On each day of 10 non-consecutive
days, 1 WHO panel and 2–3 secondary panels were tested using RT-ddPCR
in 4 replicates for the MR1 (10% BCR-ABLIS) to MR4 (0.01% BCR-ABLIS)
samples and in 8 replicates for the MR4.5 (0.0032% BCR-ABLIS) sample, to
enhance assay precision. Data analysis was performed using the statistical
methods described by White et al.14
Reverse-transcription droplet digital PCR
RNA extraction from the secondary panel was performed using RNeasy
mini kits (Qiagen, Hilden, Germany). Reverse transcription was performed
using ABI High Capacity cDNA reverse-transcription kit (Thermo Fisher
Scientific, Waltham, MA, USA) and ddPCR was performed using 2X ddPCR
Supermix (Bio-Rad, Hercules, CA, USA) on the QX-100 or QX-200 ddPCR
system (Bio-Rad). All primer and probe sequences are listed in Table 1. BCR-
ABL1 and reference genes were run as singleplex reactions in separate
wells. To achieve optimal assay precision and avoid signal saturation, cDNA
input for BCR-ABL1 per 20 μl reaction was 80 ng for the MR1 sample, 400 ng
for the MR2 sample and 675 ng for samples ⩽MR3. cDNA input for
reference genes was 10 ng per 20 μl reaction for all three reference genes.
For each RT-ddPCR run, wells with 49025 accepted droplets were
considered valid as per the manufacturer’s recommendations.
RESULTS
Manufacturing and IS calibration of the WHO BCR-ABL1 secondary
reference panel
We successfully manufactured 412 000 vials of secondary BCR-
ABL1 lyophilized cell reference panel, using the same K562 and
HL-60 cell lines and following similar manufacturing procedures as
the primary WHO panel (Supplementary Information).14 An MR4.5
level was added to the secondary panel, to enable more accurate
IS calibration at this critical level, as CML patients reaching this
deep molecular response are increasingly being considered for
treatment cessation. Quality-control assessments indicated that
the secondary panel had minimal residual moisture, excellent vial-
to-vial homogeneity and 42.5 years of real-time stability
(Supplementary Information).
To calibrate the secondary panel to the WHO `first International
Genetic Reference Panel for quantitation of BCR-ABL1 mRNA', we
followed the study design described by White et al.,14 except that
the sample size was doubled to strengthen the statistical power
(Supplementary Information). RT-ddPCR was chosen as the
calibration method, owing to its superior sensitivity, precision
and absolute quantification capability compared with RT-
qPCR.17,18 At the time of this study, no commercially available
BCR-ABL1 test used BCR or GUSB as reference genes. We
developed three sets of RT-ddPCR assays, including BCR-ABL1/
ABL1, BCR-ABL1/BCR and BCR-ABL1/GUSB, to enable IS calibration of
Table 1. Primer and probe sequences for the RT-ddPCR assays
Gene Primer/probe Sequence (5′–3′)
BCR-ABL1 Forward primer CCGCTGACCATCAATAAGGAA
FAM MGB probe AAGCCCTTCAGCGGC
Reverse primer CTGAGGCTCAAAGTCAGATGCTACT
ABL1 Forward primer ACCACTGACGTGCCTGAGATG
FAM MGB probe AGAGAGCGATCCTCTGG
Reverse primer GAGACACGGCAGGCTCATG
BCR Forward primer CACTCAGCCACTGGATTTAAGC
FAM MGB probe CCTGGAGGTGGATTC
Reverse primer CGCGTCTTTGCTTTATTCACAA
GUSB Forward primer ACGCAGAAAATACGTGGTTGG
FAM MGB probe CTCATTTGGAATTTTGCCGAT
Reverse primer GCCGAGTGAAGATCCCCTTT
Abbreviation: RT-ddPCR, reverse-transcription droplet digital PCR.
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the secondary panel against all three reference genes. All RT-ddPCR
assays were validated following a combination of industry best
practices, Minimum Information for Publication of Quantitative Real-
Time PCR Experiments guideline, and Clinical and Laboratory
Standards Institute guideline, to ensure proper accuracy, precision,
sensitivity and linearity were achieved (Supplementary
Information).19–22 Using methods described by White et al.,14 we
determined the IS CF for the RT-ddPCR assays to be 0.93 for
BCR-ABL1/ABL1, 1.85 for BCR-ABL1/BCR and 1.28 for BCR-ABL1/GUSB.
Each CF was subsequently applied to the empirical %BCR-ABL1
of the secondary panel measured by RT-ddPCR, to obtain the
assigned %BCR-ABL1IS values (Figure 1 and Table 2a). We found
that the mean %BCR-ABL1 for each level of the secondary panel
met all targeted BCR-ABL1 levels and were within 1.3-fold of the
WHO standards values. The assigned %BCR-ABL1IS of level E was
0.0038%, 0.0050% and 0.0029% for ABL1, BCR and GUSB,
respectively, indicating that an MR4.5 level was successfully
created. Moreover, the mean copy number of BCR-ABL1, ABL1,
BCR and GUSB per ng of RNA measured using RT-ddPCR was
highly similar between the WHO and secondary panels (Table 2b).
This demonstrated that the secondary panel replicated the
primary WHO panel faithfully, with the successful addition of an
MR4.5 level.
Laboratory evaluation of the WHO BCR-ABL1 secondary reference
panel
Study design. The secondary panel was sent to 44 clinical
laboratories from 24 countries worldwide for evaluation, including
34 laboratories from Europe (Supplementary Table 2). One
laboratory tested the panel with two different BCR-ABL1 assays,
resulting in a total of 45 BCR-ABL1 tests included in this report. The
laboratories were asked to conduct two studies with the
secondary panel. In Study 1, to determine the optimal sample
input of the secondary panel specific for each BCR-ABL1 test, a
standard curve experiment was run with Vial A (MR1) and Vial C
(MR3) of the panel using 50, 100, 200 and 400 ng of RNA (for one-
step assays) or cDNA (for two-step assays) input per PCR reaction;
three replicates were run per sample at each input level
(Figures 2a and b). In Study 2, to assess the usability of the
secondary panel and performance of the BCR-ABL1 tests,
laboratories used the optimal sample input determined in Study
1 to test three sets of the panel on six different days (Figure 2c).
Study 1: sample input optimization. The WHO panel did not offer
recommendations on sample input for IS calibration. Nonetheless,
sample input outside of the linear dynamic range of a RT-qPCR
assay might potentially lead to inaccurate results. Thus, we
designed a standard curve experiment to help laboratories
determine the optimal sample input of the secondary panel for
their BCR-ABL1 tests (Figures 2a and b). Surprisingly, approximately
half of the tests showed different %BCR-ABL1 results against
different sample inputs of the same sample (Po0.05), even when
data from either the highest or lowest sample input were allowed
to be removed based on auxiliary-pick-regression analysis
(Figure 3 and Supplementary Information). Among the 42 assays
that tested Vial A (MR1), 29% (12 of 42) showed decreasing
%BCR-ABL1 with increasing sample input (Figure 3d) and 24%
(10 of 42) showed increasing %BCR-ABL1 (Figure 3g and
Supplementary Figure 2). Among the 45 assays that tested Vial
C (MR3), 22% (10 of 45) showed decreasing %BCR-ABL1 with
increasing sample input (Figure 3d) and 18% (8 of 45) showed
increasing %BCR-ABL1 (Figure 3g and Supplementary Figure 3).
In this study, we observed that the mean standard deviation
(s.d.) in %BCR-ABL1 measurements from all 45 assays was 0.2log,
which was mathematically equivalent to a 1.6-fold difference in
the linear scale. Based on recommendations by Thiers et al.,23 1 s.
d. (0.2log) was considered the optimal cutoff value for
determining differences in measurements in this study. Selecting
1 s.d. as the cutoff value took into consideration the fact that a
o1-s.d. cutoff value would require a substantially larger sample
Figure 1. The BCR-ABL1 secondary reference panel was calibrated to
the WHO standards using RT-ddPCR against (a) ABL1, (b) BCR and
(c) GUSB for IS conversion (n= 40 from MR1 to MR4, n= 80 for MR4.5).
The IS CFs for the RT-ddPCR assays were determined to be 0.93 for
the BCR-ABL1/ABL1 assay, 1.85 for the BCR-ABL1/BCR assay and 1.28
for the BCR-ABL1/GUSB assay. Blue dotted lines represent the
nominal %BCR-ABL1 value of the WHO panel at different levels.
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size to be considered statistically robust, whereas 41 s.d. would
increase the number of misclassifications.23 Thus, in this study, a
mean difference of ⩾ 0.2log in %BCR-ABL1 value at different
sample inputs by the same test was considered as beyond the
inherent variability of an assay. We found that among the assays
that showed changing %BCR-ABL1 against different sample
inputs, 55% (12 of 22) at MR1 and 78% (14 of 18) at MR3 obtained
results with ⩾ 0.2log difference. Overall, these results showed that
some BCR-ABL1 tests were nonlinear and might therefore yield
statistically different %BCR-ABL1 results against different sample
inputs. To mitigate the risk of inaccurate %BCR-ABL1 measure-
ments from using an inappropriate sample input, it is highly
recommended that laboratories standardize CML patient sample
inputs by quantifying the extracted RNA before performing
RT-qPCR.
To further investigate the cause of the unstable %BCR-ABL1
measurements across different sample inputs, we calculated
the PCR efficiency and efficiency ratio for each individual
BCR-ABL1 and reference gene assay using the formula ‘Efficiency =
− 1+10(−1/slope)’ (Supplementary Information).24 A well-optimized
PCR assay should have PCR efficiency between 0.9 and 1.1,25
which would result in a PCR efficiency ratio of ~ 1 between the
BCR-ABL1 and reference gene assays. Indeed, we found that most
assays that successfully achieved stable %BCR-ABL1 across
different sample inputs had a PCR efficiency close to 1 for both
the BCR-ABL1 and reference gene assays, resulting in a mean
efficiency ratio of 1.03 (n= 43; abnormal efficiency ratios of o0
and 410 were excluded from the analysis) (Figures 3a–c). Assays
that showed decreasing %BCR-ABL1 against increasing sample
input had a mean PCR efficiency ratio of 1.51 (n= 20) (Figures 3d–f),
whereas assays that showed increasing %BCR-ABL1 had a mean
PCR efficiency ratio of 0.63 (n= 16) (Figures 3g–i). This indicated
that the lack of stability in %BCR-ABL1 against sample input was
directly correlated with suboptimal PCR efficiency. Surprisingly,
Table 2. The BCR-ABL1 secondary reference panel was highly concordant with the WHO panel
Reference gene RT-ddPCR IS CF WHO panel Secondary panel
Panel member Mean empirical
%BCR-ABL1
Nominal
%BCR-ABL1IS
Panel
member
Mean empirical
%BCR-ABL1
Assigned
%BCR-ABL1IS
(a) Empirical and %BCR-ABLIS values
ABL1 0.93 4 (08/198) 11.2250 10.7469 A 13.7178 12.7575
3 (08/196) 1.2540 1.1672 B 1.2841 1.1942
2 (08/194) 0.1260 0.1112 C 0.1095 0.1019
1 (08/192) 0.0130 0.0118 D 0.0116 0.0108
E 0.0041 0.0038
BCR 1.85 4 (08/198) 9.8135 16.3129 A 11.5502 21.3678
3 (08/196) 0.8441 1.6627 B 0.7300 1.3505
2 (08/194) 0.0988 0.1753 C 0.0759 0.1404
1 (08/192) 0.0098 0.0195 D 0.0081 0.0150
E 0.0027 0.0050
GUSB 1.28 4 (08/198) 6.5834 10.1235 A 9.1800 11.7504
3 (08/196) 0.5924 0.8295 B 0.6219 0.7960
2 (08/194) 0.0677 0.0749 C 0.0628 0.0804
1 (08/192) 0.0065 0.0071 D 0.0068 0.0087
E 0.0023 0.0029
Reference gene WHO panel Secondary panel
Panel member Mean copy number per ng RNA Panel member Mean copy number per ng RNA
(b) Copy numbers of BCR-ABL1, ABL1, BCR and GUSB per ng of RNA
BCR-ABL1 4 (08/198) 92.98 A 103.27
3 (08/196) 9.75 B 8.56
2 (08/194) 0.99 C 0.72
1 (08/192) 0.10 D 0.08
E 0.03
ABL1 4 (08/198) 831.74 A 754.55
3 (08/196) 778.56 B 665.80
2 (08/194) 784.95 C 651.95
1 (08/192) 785.90 D 653.85
E 642.71
BCR 4 (08/198) 948.59 A 973.44
3 (08/196) 1036.91 B 1058.25
2 (08/194) 1004.05 C 1012.51
1 (08/192) 1033.21 D 1079.15
E 1017.74
GUSB 4 (08/198) 1380.43 A 1198.94
3 (08/196) 1454.12 B 1238.22
2 (08/194) 1390.83 C 1261.53
1 (08/192) 1388.23 D 1283.79
E 1244.11
Abbreviations: CF, conversion factor; IS, International Scale; RT-ddPCR, reverse-transcription droplet digital PCR; WHO, World Health Organization.
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BCR-ABL1 and reference gene assays that were suboptimal in a
similar manner could artificially cancel each other’s defects to
achieve artificially stable %BCR-ABL1 results (Figures 3j–l). Overall,
these results illustrated that both the BCR-ABL1 and reference
gene assays needed to be properly optimized and validated, in
order to achieve good quality %BCR-ABL1 testing.26–28
As different assays had different linear dynamic ranges, we
observed a 430-fold range of optimal sample input for the
secondary panel calculated for the different BCR-ABL1 tests.
Interestingly, among the 31 laboratories that routinely quantified
their CML patient sample inputs, the reported patient sample
input was on average 2.4-fold higher than the calculated optimal
input of the secondary panel, after two extreme outlier values of
11.6- and 48.3-fold were identified using robust regression
analysis and excluded from the calculation (Supplementary
Information). This was concordant with the fact that although
the mean copy number of ABL1, BCR and GUSB per ng of RNA in
the secondary panel was 674, 1028 and 1245 (Table 2b), the mean
copy per ng of human EDTA anticoagulated blood RNA was only
289 for ABL1 (n= 40), 750 for BCR (n= 6) and 420 for GUSB (n = 5)
(data not shown). These results indicated that the optimal sample
input of the secondary panel was approximately half of the patient
sample input typically used by the laboratory in terms of ng RNA
or cDNA. Thus, when using the secondary panel, laboratories
might consider using twofold less cDNA input per PCR reaction
compared with CML patient samples, to achieve similar copy
numbers and avoid exceeding the linear dynamic range of their
assay. Nonetheless, it is recommended that laboratories perform a
similar standard curve experiment to identify the optimal sample
input specific for their assay before using the secondary panel for
the first time. The optimized sample input should maximize copy
number detection but minimize potential PCR inhibition caused
by carryover from the reverse-transcription reactions.
Study 2: performance of clinical BCR-ABL1 tests on the secondary
panel. A robust BCR-ABL1 test should demonstrate good IS
accuracy, precision and sensitivity within statistical limits, espe-
cially at the lower disease levels. In Study 2, laboratories were
asked to use the optimal sample input determined in Study 1 to
test three sets of the secondary panel on six different days,
following the design previously used by White et al. (Figure 2c).14
Results from each assay were subsequently analyzed to assess
accuracy, precision and sensitivity. For IS accuracy, the overall
mean %BCR-ABL1 from all 45 assays, calculated using robust
Figure 2. Study design for the international multi-center evaluation of the secondary panel, including (a) Study 1 for one-step RT-qPCR tests,
(b) Study 1 for two-step RT-qPCR tests and (c) Study 2.
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Figure 3. Examples of different assay results from Study 1 of the multi-center evaluation study. A properly optimized assay should yield similar
%BCR-ABL1 results at different sample inputs and both the BCR-ABL1 and reference gene assays should have a PCR efficiency close to 1 (a–c).
Some assays showed decreasing %BCR-ABL1 measurements with increasing sample input (d–f), whereas others showed increasing %BCR-
ABL1 measurements instead (g–i). The PCR efficiency of these assays tended to be suboptimal (o0.9 or 41.1), resulting in disproportional
increase of BCR-ABL1 or reference gene copy number with increasing sample input (e, f, h and i), which subsequently led to the unstable
%BCR-ABL1 measurements (d and g). Occasionally, BCR-ABL1 and reference gene assays that were suboptimal in a similar manner could cancel
each other’s defects, to achieve artificially stable %BCR-ABL1 measurements (j–l). Red lines represent the linear regression fit based on actual
data and blue lines represent what ideal data should resemble.
BCR-ABL secondary reference panel
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regression analysis to minimize effects of outliers, were highly
concordant with the assigned values of the secondary panel
(Table 3 and Supplementary Figure 5). The mean ratios for all
reference genes at all levels were within 1.5-fold or 0.16log of the
panel’s assigned values, with the exception of Vial D (MR4) for
GUSB, which differed by 1.7-fold/0.24log. For results from
individual assays, 60% (27 of 45) obtained mean %BCR-ABL1
within twofold of the panel’s assigned values at all levels
(Supplementary Figure 5). The observed concordance was most
likely due to three factors. First, optimal sample input calculated in
Study 1 was used for each assay, thus restricting the PCR reactions
within the assay’s linear dynamic range. Second, even though
many different assay configurations were used by the laboratories
(Supplementary Table 2), 60% (27 of 45) followed the EAC
recommendations for the PCR primer design26 and 18% (8 of 45)
used commercial BCR-ABL1 kits (Supplementary Table 2 and
Supplementary Figure 5), which are generally well optimized and
validated. Lastly, 51% (23 of 45) of assays were IS calibrated via
sample exchange with the reference laboratory in Mannheim,
Germany, and 20% (9 of 45) with Adelaide, Australia. This
demonstrated that BCR-ABL1 tests can be effectively harmonized
by using the same PCR primer designs and by standardizing
the IS calibration process. Thus, commercial availability of a
common IS reference material could contribute to worldwide IS
standardization.
Most clinical samples are typically run in only one or two
replicates, which requires a high degree of assay precision to
ensure accuracy of each of the final BCR-ABL1 test results. To
enable ⩾ 95% confidence for the true value of a CML patient
sample to be within 0.5log on each side of the measured value, an
s.d. of p0.25log for the BCR-ABL1 test is required. Accordingly,
if a sample is measured at MR4.5, there will be ⩾ 95% confidence
that the true value of the sample is not above MR4 or below MR5.29
We calculated the intra-lab s.d. for each BCR-ABL1 test and noted
that 84% (38 of 45) successfully achieved an s.d. of p 0.25 log
from MR1 to MR4. For BCR-ABL1 tests that obtained 4 0.25log s.d.,
precision may be improved by performing further assay optimiza-
tion and increasing the number of replicates per patient
sample.28,30
For monitoring deep molecular response, good BCR-ABL1 assay
sensitivity and precision are key performance characteristics. In
Study 2, we found that 93% (42 of 45) assays successfully detected
all replicates at MR4 and 76% (34 of 45) detected all replicates at
MR4.5. To further understand how sample input affected assay
sensitivity and precision, we analyzed results from the 32 ABL1
assays, as this provided the largest sample size. Among the ABL1
assays, 56% (18 of 32) detected all replicates at MR4.5 and achieved
p0.25log s.d., 19% (6 of 32) detected all replicates but had
4 0.25log s.d. and 25% (8 of 32) assays had at least 1 undetected
replicate. Logistic regression analysis showed a strong positive
correlation between increased sample input and increased
detection rate (P= 0.001). In addition, the median ABL1 copy
number per PCR reaction was 98 202 for laboratories that
achieved good detection rate and precision, 74 923 for those
that achieved good detection rate but suboptimal precision and
29 717 for those that had undetected replicates at MR4.5, further
illustrating that an increased sample input could improve the
sensitivity and precision of MR4.5 detection.
The laboratories that participated in this study used diverse
assay configurations for BCR-ABL1 testing (Supplementary Table 2).
To determine whether assay configurations affected assay
performance in terms of IS accuracy, precision and sensitivity,
we performed Bayesian average analysis and found no statistically
significant relationship between assay performance versus choice
of reference gene, RNA extraction method and the usage of
commercial versus laboratory-developed tests. Interestingly,
among the assays that successfully achieved good accuracy
(within twofold of assigned values), good precision (p0.25log s.d.)
and good MR4.5 sensitivity (no undetected replicate), 82% (14 of
17) showed stable %BCR-ABL1 measurements against sample
inputs at MR3 in Study 1, compared with 46% (13 of 28) among
assays with less optimal assay performance. This illustrated that
although BCR-ABL1 assays of different designs can perform equally
well, proper PCR optimization is required to ensure good clinical
performance. Interestingly, the number of assays that achieved
good precision (84%) and MR4.5 sensitivity (76%) exceeded the
number that achieved good IS accuracy (60%), indicating that
there remains an unmet need for a simple and broadly available IS
calibration mechanism.
Calculating WHO IS CF from the secondary panel. Using the
assigned BCR-ABL1 IS values of the secondary panel, it was
possible to calculate an IS CF traceable to the WHO panel for each
test. Before CF calculation, Bland–Altman analysis was performed
Table 3. Summary results of the secondary panel international multi-center evaluation study
Reference gene Number of
assays
Vial
(WHO/secondary panel)
%BCR-ABL1IS
WHO panel
Nominal
Secondary panel
Assigned
Results from 45 BCR-ABL1 assays
Mean s.d. Minimum Maximum
ABL1 32 4 (08/198)/A 10.7469 12.7575 11.4450 8.2225 3.6127 37.4603
3 (08/196)/B 1.1672 1.1942 1.1771 0.9994 0.4014 4.4109
2 (08/194)/C 0.1112 0.1019 0.1013 0.0931 0.0362 0.4553
1 (08/192)/D 0.0118 0.0108 0.0110 0.0232 0.0033 0.1323
NA/E 0.0038 0.0038 0.0038 0.0013 0.0159
BCR 5 4 (08/198)/A 16.3129 21.3678 21.3999 12.3547 13.6781 42.5295
3 (08/196)/B 1.6627 1.3505 1.7243 1.2662 1.0215 4.2655
2 (08/194)/C 0.1753 0.1404 0.1615 0.0863 0.0881 0.3025
1 (08/192)/D 0.0195 0.0150 0.0153 0.0105 0.0071 0.0302
NA/E 0.0050 0.0056 0.0047 0.0028 0.0134
GUSB 8 4 (08/198)/A 10.1235 11.7504 8.9008 3.7900 4.5344 14.9359
3 (08/196)/B 0.8295 0.7960 0.7346 0.4133 0.3514 1.5494
2 (08/194)/C 0.0749 0.0804 0.0587 0.0351 0.0218 0.1149
1 (08/192)/D 0.0071 0.0087 0.0050 0.0033 0.0010 0.0106
NA/E 0.0029 0.0020 0.0018 0.0005 0.0054
Abbreviations: NA, not applicable; WHO, World Health Organization.
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for each assay as described by White et al.,14 to assess whether
bias was linear across the %BCR-ABL1 range. Of all the assays, 69%
(31 of 45) showed no statistically significant trend in the Bland–
Altman analysis, indicating that a valid CF could be calculated for
these assays and compared with the laboratory’s current CF, most
of which were obtained from sample exchange. Mathematically,
when the ratio between the assay’s current CF and the CF
calculated from the secondary panel is o0.63 or 41.58, the
resulting %BCR-ABL1 values will have a 40.2log difference
(Supplementary Information). Among the 31 assays, 58% (18 of
31) achieved a CF ratio between 0.63 and 1.58, indicating that
their current CF was equivalent to the CF from the secondary
panel. This was concordant with the fact that 60% of assays
obtained mean %BCR-ABL1 within twofold of the panel’s assigned
values. This also indicated that the secondary panel can be
effectively used to obtain IS CFs equivalent to sample exchange.
DISCUSSIONS
In this study, we successfully created the first cell-based BCR-ABL1
secondary reference panel that faithfully replicated the WHO BCR-
ABL1 International Genetic Reference Panel in both raw material
and manufacturing methods,14 with an additional MR4.5 level. The
secondary panel was manufactured under Good Manufacturing
Practice and confirmed to have low residual moisture content,
vial-to-vial homogeneity and 42.5-year stability. BCR-ABL1 IS
values traceable to the WHO panel were assigned to the
secondary panel using RT-ddPCR against ABL1, BCR and GUSB.
Both the assigned IS values and absolute copy numbers of the
secondary panel were found to be highly concordant with the
primary WHO standards.
Many of the 44 laboratories that participated in the secondary
panel evaluation currently act as a national reference laboratory
for their country. The panel was successfully processed by all
laboratories, indicating that it is compatible with many different
BCR-ABL1 test configurations. Through a standard curve experi-
ment, we found that close to half of the tests showed signs of
inadequate PCR optimization such as poor linearity against
different sample inputs and suboptimal PCR efficiency. Interest-
ingly, when a customized optimal sample input was used, 60% (27
of 45) of assays achieved mean %BCR-ABL1 values within twofold
of the panel’s assigned values, 84% (38 of 45) achieved good
precision (⩽ 0.25log s.d.) from MR1 to MR4 and 76% (34 of 45)
achieved 100% detection rate down to MR4.5. Three factors
probably contributed to these excellent results: usage of a
validated optimized sample input specific to the assay, the fact
that 78% (35 of 45) assays used either the EAC primer design or a
commercial kit and that 71% (32 of 45) assays were IS calibrated
via sample exchange with one of the two major international
reference centers. This indicated that using published assay
designs and a harmonized IS calibration approach may lead to
BCR-ABL1 test standardization. Nonetheless, we noted that the
number of assays that achieved good precision and sensitivity
exceeded the number that achieved good IS accuracy, indicating
that there remains an unmet need for a simple and broadly
available calibration mechanism, such as this secondary panel, to
ensure IS accuracy is maintained in laboratories over time.
We also showed that different assay designs including different
reference genes, RNA extraction methods and usage of commer-
cial kits versus laboratory-developed tests did not affect assay
performance. Nonetheless, better PCR optimization correlated
with better assay performance and increased sample input
improved detection rate and precision at MR4.5. In addition to
being a reference sample for IS calibration,14 the secondary
reference material and its derivatives could also be used in assay
analytical validation and optimization. For example, it can be used
as standardized samples in External Quality Assessment programs
for proficiency testing,31 especially as nominal values (that is,
correct answers) are available for each member of the panel.
Second, it can become a source of positive control samples to be
run alongside patient samples for quality assurance. This can
become especially powerful when multiple laboratories partici-
pate in a peer group quality-control monitoring program, in which
results from such positive control samples are compared and
monitored regularly. Lastly, the MR4.5 sample in the reference
panel can be used to validate the sensitivity and MR4.5 detection
capability of an assay.
In conclusion, a secondary reference panel traceable to the
WHO panel with an additional MR4.5 level can provide easier
access to IS calibration, as well as act as a tool for assay
optimization, validation and quality assurance.
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